Calaspargase pegol-mknl - Biologic Drug Details

Summary for calaspargase pegol-mknl

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for calaspargase pegol-mknl

Established Pharmacologic Class	Asparagine-specific Enzyme
Chemical Structure	Asparaginase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for calaspargase pegol-mknl Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for calaspargase pegol-mknl Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for calaspargase pegol-mknl Derived from Patent Text Search

No patents found based on company disclosures

Calaspargase pegol-mknl Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for Calaspargase Pegol-mknl?

Calaspargase pegol-mknl is a long-acting asparaginase used in treating acute lymphoblastic leukemia (ALL), primarily in pediatric and adult populations. Its market depends on several factors including competition, regulatory status, and clinical adoption.

Clinical and Regulatory Status

• Approved in the U.S. in 2021 under the brand name Asparlas (EUSA Pharma) for ALL.
• Approved in the European Union and other jurisdictions.
• FDA approval was based on favorable pharmacokinetics, safety, and efficacy data.

Competition Landscape

• Competing drugs include Oncaspar (pegaspargase), Erwinase (alkaloid-based asparaginase), and emerging biosimilars.
• Oncaspar remains dominant due to earlier market entry, established payer coverage, and widespread clinical adoption.
• Calaspargase's extended half-life (approximately 3 weeks) offers advantages in dosing schedules over Oncaspar (7-14 days).
• Biosimilar development could pressure prices but has faced delays due to patent and manufacturing challenges.

Market Drivers

• Increasing global incidence of ALL, especially in pediatric populations.
• Growing use of combination therapies incorporating asparaginase.
• Preference for less frequent dosing schedules improves patient compliance and reduces healthcare costs.

Barriers

• High manufacturing costs for biologics limit pricing flexibility.
• Payer access and formulary inclusion are slow in some regions.
• Need for expanded indications outside initial approvals.

Regional Variability

• United States: Faster adoption driven by established treatment guidelines and insurance coverage.
• Europe: Growing adoption, with some delays due to regulatory processes in member countries.
• Asia-Pacific: Expanding market but still in early stages due to pricing and healthcare infrastructure differences.

What Is the Financial Trajectory for Calaspargase Pegol-mknl?

Revenue Projections

• Estimated to reach approximately $150–200 million globally in 2023 according to market intelligence reports [1].
• Sales expected to grow at a compound annual growth rate (CAGR) of 15–20% over the next five years, contingent on market penetration and extension into new indications.

Key Revenue Drivers

• Adoption rate increases in North America and Europe.
• Expansion into additional indications such as lymphoma.
• Cost efficiencies from manufacturing scale-up.

Cost Structure and Profitability

• Manufacturing costs are high, typical for complex biologics.
• Pricing varies by region: in the US, list prices range from $20,000 to $30,000 per treatment course.
• Margins are currently under pressure due to high R&D and manufacturing costs and reimbursement negotiations.

Challenges Impacting Financial Trajectory

• Potential entry of biosimilars could lower prices.
• Regulatory delays or adverse safety data could hamper sales growth.
• Competition from newer biologics or alternative therapies may reduce market share.

Future Outlook

• Launch of additional clinical trials aiming to extend indications can boost revenue streams.
• Partnership deals with global pharma entities may accelerate adoption.
• Cost reductions from manufacturing efficiencies could improve margins.

Key Considerations for Investors and R&D Stakeholders

• The biologic’s competitive edge hinges on its extended half-life, which offers dosing advantages.
• Market growth is driven by increasing global prevalence and improved treatment protocols.
• Price pressures and biosimilar competition remain significant risks.
• Market entry barriers in certain regions suggest dependence on regional regulatory environments.

Key Takeaways

• Calaspargase pegol-mknl is in its growth phase, with revenue projections indicating steady expansion into global markets.
• The primary drivers are dosing convenience and increasing indication expansion.
• Competition from Oncaspar, biosimilars, and future therapies could influence market share and prices.
• High manufacturing costs and regulatory landscapes shape the financial trajectory.

FAQs

1. What makes calaspargase pegol-mknl different from other asparaginases?
It has an extended half-life of about three weeks, reducing dosing frequency compared to alternatives like Oncaspar (7-14 days), potentially improving compliance and reducing healthcare costs.

2. How does the regulatory landscape affect its market access?
FDA approval in 2021 facilitated US market entry; European and other approvals followed. Variability in regional regulatory timelines and reimbursement policies can delay market growth.

3. What are the primary challenges to its widespread adoption?
High manufacturing costs, payer coverage restrictions, and competition from biosimilars or new therapies limit rapid expansion.

4. What is the estimated global sales volume for calaspargase pegol-mknl in 2023?
Approximately in the range of $150–200 million, with potential for growth based on indication expansion and regional adoption.

5. How might biosimilars impact its future?
Biosimilar development could decrease prices and erode market share, especially if they gain regulatory approval and clinician acceptance.

References

[1] Market intelligence reports on biologics in oncology and hematology, 2023.